Compare VIPS & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | BLLN |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | China | United States |
| Employees | N/A | 713 |
| Industry | Catalog/Specialty Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.8B |
| IPO Year | 2012 | N/A |
| Metric | VIPS | BLLN |
|---|---|---|
| Price | $15.25 | $136.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $19.58 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.9M | 593.0K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.79 | $46.29 |
| Revenue Next Year | $2.05 | $30.14 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.65 | $61.96 |
| 52 Week High | $21.08 | $139.79 |
| Indicator | VIPS | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 69.23 | 63.32 |
| Support Level | $14.78 | $79.07 |
| Resistance Level | $15.87 | $138.70 |
| Average True Range (ATR) | 0.37 | 7.53 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 98.05 | 81.68 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.